Compare Repligen Corporation Common Stock (RGEN) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Toronto-Dominion Bank — how do they compare? Repligen Corporation Common Stock trades at $184.78 (market cap $11.31B), while Toronto-Dominion Bank trades at $118.98 (market cap $192.46B). The key difference: Toronto-Dominion Bank is far larger — about 17× Repligen Corporation Common Stock's market cap, and Toronto-Dominion Bank pays a 2.67% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Toronto-Dominion Bank for 85 Days on average.
| RGEN | TD | |
|---|---|---|
Market Cap | $11.31B | $192.46B |
Volume | 1,216,919 | 2,419,463 |
Sector | Health | Financials |
52-Week High | $194.57 | $124.80 |
52-Week Low | $102.87 | $78.72 |
Typical Hold Time | 0 Days | 85 Days |
Enterprise Value | $11.20B | $567.89B |
Dividend Yield | — | 2.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
TD stock trades at $117.95, up 1.25% today, with a bearish technical signal but strong fundamentals. Recent earnings consistently beat estimates, with Q2 2026 EPS of $1.98 exceeding the $1.74 forecast. The company announced a $10 billion share buyback program (Proactive Investors, 2026-09-30) and a $108 billion commitment to Canadian infrastructure (WSJ, 2026-09-14), signaling confidence in growth. Valuation ratios include a P/E of 17.99 and net income margin of 24.88% for 2025.
The outlook is mixed: strong profitability and analyst buy consensus (52.94%) support upside, but bearish technicals and volatile cash flows pose risks. Key opportunities include expansion initiatives, while risks involve debt levels and economic sensitivity. The stock's performance hinges on execution of strategic investments amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
